BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:CCTx-001 readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of CCTx-001\, from ClinicalTrials.gov estima
 tes.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06281847-3076@assetmemo.bio
DTSTAMP:20261121T005828Z
DTSTART;VALUE=DATE:20270731
DTEND;VALUE=DATE:20270801
SUMMARY:CCTx-001: Phase 1/2 readout est. (NCT06281847)
DESCRIPTION:CCTx-001\, phase 1/2\, Acute Myeloid Leukemia.\nStudy: An Adapt
 ive Open-label Multicentre Phase 1/2 Trial\, to Determine the Recommended 
 Phase 2 Dose of CCTx-001\, and to Assess Safety\, Tolerability\, and Clini
 cal Activity in Patients With Relapsed/Refractory Acute Myeloid Leukaemia\
 nEstimated primary completion: July 2027. This is a ClinicalTrials.gov est
 imate\, not a confirmed readout date\, and it can move.\nDrug page: https:
 //assetmemo.bio/drug/cctx-001#upcoming-events\nRegistry record: https://cl
 inicaltrials.gov/study/NCT06281847
URL:https://assetmemo.bio/drug/cctx-001#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
